Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-12-15 Director's Dealing
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change of Director`s Interest Notice - Delaat 2 pages 81.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a company director, including shares acquired and disposed, and the nature of the interest. This type of document is a regulatory filing specifically reporting personal share transactions by company directors and executives, commonly known as insider trades. It is not a full financial report, earnings release, or management announcement. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content confirm it is a detailed notice of director's interest changes, not an announcement or summary of another report.
2011-12-15 English
Change of Director`s Interest Notice - J Villiger 2 pages 81.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and contains detailed information about a director's change in shareholding, including the number of securities held before and after the change, the nature of the interest, and the date of change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider trading or director share transactions. The content is specific to a director's personal share transactions and does not include financial performance data, management discussion, or other report types. Therefore, it fits the definition of 'Director's Dealing' (DIRS). The document length is 3584 characters, which is typical for such notices and not a report publication announcement or regulatory filing fallback. Confidence is high due to clear matching of content to the DIRS category.
2011-12-15 English
Change of Director`s Interest Notice - D Hanley 2 pages 81.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including acquisitions and disposals of shares and options. The content focuses on personal share transactions by a director, including dates, number of shares/options before and after the change, and the nature of the transactions. There is no financial performance data, earnings information, or management discussion. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4432 characters, which is sufficient for a detailed notice but not a full financial report. Therefore, the correct classification is DIRS (Director's Dealing).
2011-12-15 English
Results of Retail Entitlement Offer 2 pages 87.6KB
Capital/Financing Update Classification · 100% confidence The document is a media release dated 13 December 2011 from Pharmaxis Ltd announcing the results of a Retail Entitlement Offer, which is a capital raising event. It details the amount raised, subscription rates, settlement dates, and underwriters involved. There is no financial statement or detailed financial analysis present, only an update on the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2011-12-12 English
Phase 3 Trial in Bronchiectasis Reaches Recruitment Target 2 pages 113.1KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing that a major Phase III clinical trial for the drug Bronchitol has reached its recruitment target. It provides details about the trial design, locations, and the condition being treated (bronchiectasis). The document is dated December 2011 and is clearly a public announcement rather than a detailed financial or regulatory report. There are no financial statements, regulatory filings, or detailed management discussions present. The content focuses on clinical trial progress and company product development news. This fits best into the category of a Regulatory Filing (RNS) as a general announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Investor Presentation. The document length (7879 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2011-12-12 English
Appendix 3B 11 pages 109.9KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new shares, including the number of shares issued, terms of the securities, issue price, purpose of the issue, dates of allotment, underwriting details, and brokers involved. It references ASX rules and is clearly an official announcement related to a capital raising event. The content focuses on the issuance and quotation of additional securities rather than financial results or management commentary. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive details, not just a brief announcement or a certification, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2011-11-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.